CompletedNCT00829881
Betahistine for focus and attention in adults with ADHD
About this title
Read the official source — NCT00829881Medication studyAges 22–55United States
Understand this study
Who was this study for?
Listed age limits: 22 years to 55 years.
- Listed locations
- CincinnatiSee all locations and recruitment
- Participation duration
- About 4 weeks
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateJanuary 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- P2D, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 22 Years to 55 Years
- Official registry ID
- NCT00829881
- Official title
Show the full official title
Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cincinnati
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is P2D, Inc.
Did this study involve medication?
Yes. The study involved medication, including Betahistine Hydrochloride and Placebo Capsule.
Who was this study for?
Listed age limits: 22 years to 55 years.
